- Home
- IRON vs SXI Comparison
IRON vs SXI Comparison
Compare IRON & SXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- SXI
- Stock Information
- Founded
- IRON 2017
- SXI 1955
- Country
- IRON United States
- SXI United States
- Employees
- IRON N/A
- SXI N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- SXI Industrial Machinery/Components
- Sector
- IRON Health Care
- SXI Industrials
- Exchange
- IRON Nasdaq
- SXI Nasdaq
- Market Cap
- IRON 2.1B
- SXI 2.3B
- IPO Year
- IRON N/A
- SXI N/A
- Fundamental
- Price
- IRON $59.76
- SXI $164.76
- Analyst Decision
- IRON Strong Buy
- SXI Strong Buy
- Analyst Count
- IRON 12
- SXI 3
- Target Price
- IRON $92.08
- SXI $223.33
- AVG Volume (30 Days)
- IRON 330.3K
- SXI 114.3K
- Earning Date
- IRON 08-11-2025
- SXI 07-31-2025
- Dividend Yield
- IRON N/A
- SXI 0.78%
- EPS Growth
- IRON N/A
- SXI N/A
- EPS
- IRON N/A
- SXI 5.04
- Revenue
- IRON N/A
- SXI $748,252,000.00
- Revenue This Year
- IRON N/A
- SXI $9.67
- Revenue Next Year
- IRON N/A
- SXI $12.91
- P/E Ratio
- IRON N/A
- SXI $32.70
- Revenue Growth
- IRON N/A
- SXI 2.67
- 52 Week Low
- IRON $30.82
- SXI $128.85
- 52 Week High
- IRON $68.73
- SXI $212.66
- Technical
- Relative Strength Index (RSI)
- IRON 61.73
- SXI 57.20
- Support Level
- IRON $58.63
- SXI $154.57
- Resistance Level
- IRON $61.59
- SXI $167.58
- Average True Range (ATR)
- IRON 2.15
- SXI 3.67
- MACD
- IRON -0.14
- SXI 0.39
- Stochastic Oscillator
- IRON 64.07
- SXI 81.09
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About SXI Standex International Corporation
Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. It has five reportable segments; Electronics; Engraving; Scientific; Engineering Technologies and Specialty Solutions. The maximum revenue is generated from its Electronics segment which is a component and value-added services provider of both sensing and switching technologies as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging among others. Geographically, it derives key revenue from the United States and the rest from Asia Pacific, Europe, Middle East and South Africa (EMEA), and other regions.